Camurus has carried out a new issue of shares with preferential rights for the company’s shareholders raising approximately SEK 403 million.
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. Camurus’ shares are listed on Nasdaq Stockholm.
Camurus was advised by Mannheimer Swartling in the transaction.